Atomwise
AI drug discovery platform — the AtomNet structure-based virtual-screening primitive anchors 250+ partnerships including the $1.2B-biobucks Sanofi 5-target collaboration; founder-CEO Abraham Heifets exited May 2024 after a December 2022 30-person reduction and a pivot toward internal pipeline development. ~$174M cumulative external capital with no Series C disclosed since the 2020 $123M Series B led by B Capital Group and DCVC.
The Business
Atomwise is a San Francisco-based AI drug discovery platform founded in 2012 by Abraham Heifets and Izhar Wallach, both with PhDs from the University of Toronto. The company’s core platform is AtomNet — a structure-based deep-learning virtual-screening primitive for small-molecule drug discovery that has been applied across 600+ unique disease targets and 250+ partnerships with academic institutions, biotech companies and large pharma. The marquee pharma-anchor reference is the Sanofi strategic multi-target research collaboration valued at $1.2B in biobucks ($20M upfront plus milestone / royalty payments) centered on AtomNet-driven small-molecule discovery for up to five drug targets. In October 2023 Atomwise announced the nomination of its first AI-driven development candidate — an orally bioavailable allosteric TYK2 inhibitor targeting inflammatory disease. In April 2024 the company published results from a 318-target study highlighting AtomNet as a viable alternative to high-throughput screening, with the AI platform identifying structurally novel hits for 235 of the 318 targets evaluated. Founder-CEO Abraham Heifets departed the company in May 2024 per Endpoints News reporting; no replacement CEO has been publicly named through 2026. Cumulative external capital is approximately $174M through the 2020 $123M Series B led by B Capital Group and DCVC; no Series C has been publicly disclosed since.
Customers and Distribution
Atomwise does not file public financials; the published commercial signals are the Sanofi $1.2B-biobucks 5-target collaboration ($20M upfront), the 250+ partnership base across academic institutions, biotech companies and large pharma, and the October 2023 internal-pipeline TYK2 inhibitor candidate nomination. Distribution sits across three channels: large-pharma strategic collaborations anchored on the Sanofi deal and the broader 250+ partnership base (the principal commercial channel); academic-and-biotech research collaborations under the AIMS Awards Program (the partnership-breadth channel that anchors the 750+ academic-and-biotech collaboration count cited in Endpoints News); and the internal pipeline development pivot following the December 2022 workforce reduction. Per Endpoints News reporting, the 750+ partnerships had not yet advanced a single molecule into human testing as of the May 2024 founder-CEO exit reporting — the clinical-trajectory delivery gap is the dominant active variable on the commercial-credibility frame.
Model Strategy
Atomwise is a Verticals + Rewire play under the IM Framework eight-trajectories taxonomy as applied to healthcare AI: the primary trajectory is Verticals, with the AtomNet structure-based virtual-screening primitive positioned as vertical depth on small-molecule drug discovery against generative-AI drug-discovery platforms (EvolutionaryScale, Generate Biomedicines on biologics) and the broader AI-drug-discovery cohort. The secondary trajectory is Rewire, with the Sanofi $1.2B-biobucks 5-target collaboration plus the 250+ partnership base positioning Atomwise as a pharma-services activation layer rather than a standalone biotech — the company’s strategic pivot from pure platform-licensing toward internal pipeline development following the December 2022 reduction reinforces this framing. The D4a supplier-diversity sub-rubric was held at 6 in the v1.6ep evidence pass reflecting the AtomNet platform’s compute-supplier mix; the differentiated value layer is the structure-based virtual-screening primitive applied across 600+ unique disease targets.
At A Glance
The Numbers
Compounds screened (cumulative)
Headcount (FTE)
Funding to date
Leadership Team
Atomwise is in a leadership-transition phase — founder-CEO Abraham Heifets departed in May 2024 per Endpoints News reporting, and the company’s General Counsel Jeffrey Cerio also left in August 2024 to become Korro Bio’s general counsel. The senior team continuity beyond the founder-CEO exit is not transparently disclosed in public sources; the company’s team page is the canonical reference point for current leadership. The B Capital Group / DCVC cap table from the 2020 Series B is the load-bearing late-stage governance signal in the absence of a subsequent priced round.
IM Framework Scoring
IM’s structured assessment of Atomwise’s competitive position. The summary below is the headline; expand “Show the full analyst-grade analysis” near the bottom for the per-dimension reasoning and evidence. Methodology →
Funding History
| Date | Round | Raised | Post-money | Lead investor(s) |
|---|---|---|---|---|
| Aug 2020 | Series B | $123M | — | B Capital Group, DCVC |
| 2018 | Series A | $45M | — | Monsanto Growth Ventures, Y Combinator |
| 2012–2017 | Seed cumulative | ~$6M cumulative | — | Y Combinator, Khosla Ventures |
Cumulative external capital of approximately $174M through the 2020 $123M Series B led by B Capital Group and DCVC, plus the 2018 $45M Series A and earlier seed-stage rounds. No Series C has been publicly disclosed since the 2020 Series B per Endpoints News and named-press coverage; the absence of a follow-on priced round through the 2024 founder-CEO transition is a structural signal on the capital position. Pharma-deal economics under the Sanofi $1.2B-biobucks 5-target collaboration include $20M upfront and milestone / royalty payments contingent on candidate advancement.
Competitive Landscape
| Competitor | Positioning | Distribution edge | Threat profile |
|---|---|---|---|
| Schrödinger ((NASDAQ: SDGR)) |
Physics-based computational chemistry incumbent (free-energy perturbation, molecular dynamics) layering ML on top of a decades-old simulation stack; the established enterprise-software comparable in the category. | Public-company (NASDAQ: SDGR) direct-sales motion into pharma R&D; software-licence revenue plus internal drug-discovery programs co-funded with partners. | High — the incumbent computational-chemistry platform with the broadest pharma-customer base and the closest direct competitor on structure-based small-molecule discovery; public-company financial transparency anchors the procurement-cycle frame. |
| Isomorphic Labs ((Alphabet)) |
Alphabet-funded AlphaFold-lineage drug-discovery company spun out of DeepMind; positions on structure-prediction and generative-chemistry depth rather than the CNN virtual-screening lane Atomwise pioneered. | Pharma partnership deals as the GTM (Eli Lilly, Novartis multi-target collaborations announced 2024); no commercial software product — revenue is upfront / milestone / royalty from partners. | Medium-High — Alphabet-backed AI drug discovery spinout from DeepMind; structural advantage on the AlphaFold protein-structure-prediction primitive and the broader Alphabet R&D capital base. |
| Recursion Pharmaceuticals ((NASDAQ: RXRX)) |
Phenotypic-screening platform built on automated cell-imaging and an in-house data factory; merged with Exscientia in 2024 to add generative chemistry to the phenotypic-imaging core. | Public-company (NASDAQ: RXRX) running its own pipeline plus pharma partnerships (Roche / Genentech, Bayer, Sanofi); NVIDIA strategic investment and AWS / GCP compute partnerships anchor the platform narrative. | Medium-High — phenotypic-screening AI drug discovery company with the merged Exscientia platform (acquired 2024); public-company capital base materially larger than Atomwise’s standalone position. |
| Insitro | Daphne Koller-founded machine-learning-for-drug-discovery company with a human-genetics and functional-genomics data engine; positions on target-discovery upstream of where Atomwise’s virtual screening plays. | Pharma partnership GTM (Bristol Myers Squibb, Gilead multi-year deals); private and partnership-funded, no commercial software product. | Medium — Daphne Koller’s AI drug discovery company with deep ML and human-genetics-data integration; differentiated on the disease-area-deep approach rather than the broad virtual-screening platform. |
| EvolutionaryScale / Generate Biomedicines | Protein-language-model platforms (ESM3, Chroma) using generative models to design novel proteins and biologics — a different modality from Atomwise’s small-molecule CNN virtual screening but converging on the same pharma buyer. | Generate Biomedicines runs its own pipeline plus partnerships (Amgen, Novartis); EvolutionaryScale licenses ESM3 via API and offers enterprise contracts; both are partnership / programme-funded rather than software-seat businesses. | Medium — the generative-AI biology cohort (EvolutionaryScale’s ESM3, Generate Biomedicines on protein design) that targets the biologics modality rather than small molecules; flanking competitive pressure on the broader AI-drug-discovery investment thesis. |
Potential Risks
Founder-CEO transition — Abraham Heifets exit May 2024
Founder-CEO Abraham Heifets departed Atomwise in May 2024 per Endpoints News coverage that flagged the exit as ‘casting doubt over the startup’. The company did not publicly announce the departure at the time; the general counsel Jeffrey Cerio also left in August 2024 to become Korro Bio’s general counsel. The founder-CEO transition is the dominant active variable on the score; any new CEO appointment and the senior team continuity through 2026 are the structural watch-items. The D4e key-person dependency sub-rubric reflects this transition pressure.
Absence of disclosed Series C through 2024–2026
No Series C round has been publicly disclosed since the 2020 $123M Series B led by B Capital Group and DCVC; the December 2022 ~30-person workforce reduction and the May 2024 founder-CEO transition are the structural context for the absence of a subsequent priced round. The capital position is materially smaller than the AI-drug-discovery public-company cohort (Schrödinger, Recursion) and the Alphabet-backed Isomorphic Labs; the bull case is that capital efficiency on the AtomNet platform plus the Sanofi-anchored pharma-collaboration economics offset the absolute-capital gap; the bear case is that the absence of priced-round confirmation through the founder-CEO transition is a structural signal.
Clinical-trajectory delivery — no candidates yet in human testing
Per Endpoints News reporting, Atomwise’s 750+ partnerships with academics, biotechs and large pharma companies had not yet advanced a single molecule into human testing as of the May 2024 founder-CEO exit reporting. The October 2023 nomination of Atomwise’s first AI-driven development candidate (an orally bioavailable allosteric TYK2 inhibitor) was the published trajectory milestone; advancement to first-in-human clinical trials is the dominant clinical-credibility watch-item over the next 12–24 months.
Competitive intensity vs Schrödinger, Isomorphic Labs, Recursion
AI drug discovery is heavily contested: Schrödinger’s computational-chemistry incumbency and pharma-customer base; Isomorphic Labs’ AlphaFold-anchored platform and Alphabet R&D capital base; Recursion’s merged Exscientia phenotypic-screening platform; Insitro’s disease-area-deep approach; and the generative-AI biology cohort (EvolutionaryScale, Generate Biomedicines) on the biologics modality. The competitive intensity is the active substitution pressure on the Atomwise platform; the bull case is that the AtomNet platform’s small-molecule focus and the 250+ partnership base are the moat; the bear case is that better-capitalised competitors close the platform-breadth gap.
Regulatory exposure — FDA AI / ML guidance
AI drug discovery sits in an active regulatory zone: FDA AI / machine-learning device guidance, IND filing requirements, and AI-bias-and-validation considerations across the candidate-development pipeline. The D4c regulatory-exposure sub-rubric was held at 5 in the v1.6ep evidence pass on this elevated regulatory load shared across the cohort; any FDA-or-equivalent regulatory event at a partner pipeline is a brand-defining signal.
Recent IM Coverage
- Healthcare AI — sector landing May 2026.
- IM Framework methodology May 2026.
Show recent press coverage of Atomwise
- 2022 — Sanofi signs $1.2B pact with Atomwise in latest high-value AI drug discovery deal (Fierce Biotech)
- 2022 — Diving deeper into AI discovery, Sanofi signs 5-drug deal with Atomwise (Pharmaphorum)
- Oct 2024 — Scoop: Founding CEO leaves Atomwise, casting doubt over a once high-flying AI startup (Endpoints News)
- Aug 2020 — Drug discovery company Atomwise lands $123M in Series B funding (MobiHealthNews)
- 2024 — AI-Based Drug Discovery Company Atomwise Sets Its Sights on Inflammatory Disease Market (GEN Edge)
Show the source register for the figures on this page
IM operates a primary-source-where-possible discipline. The figures above come from:
- Revenue: Atomwise is private and does not separately disclose revenue or ARR. Pharma-collaboration economics under the Sanofi $1.2B-biobucks 5-target collaboration include $20M upfront plus milestone / royalty payments contingent on candidate advancement; the broader 250+ partnership base is not separately revenue-disclosed. We decline to publish a precise revenue figure pending a primary disclosure.
- Partnership count: Atomwise has 250+ partnerships with academic institutions, biotech companies and large pharma per company-page disclosures, covering 600+ unique disease targets. The Sanofi $1.2B-biobucks 5-target collaboration is the marquee pharma-anchor reference; the broader partnership base spans 750+ academic and biotech collaborations per Endpoints News coverage.
- Headcount: Atomwise is private and does not disclose headcount in a formal filing. Endpoints News reported a ~30-person workforce reduction in December 2022 and the company subsequently pivoted toward internal pipeline development; named-press coverage of the May 2024 founder-CEO transition does not publish a specific current headcount. We decline to publish a precise headcount and reference the Atomwise team page as the canonical entry point.
- Funding to date: Cumulative external capital of approximately $174M through the August 2020 $123M Series B led by B Capital Group and DCVC, the 2018 $45M Series A (Monsanto Growth Ventures, Y Combinator), and earlier seed-stage rounds. No Series C has been publicly disclosed; the absence of a follow-on priced round through the founder-CEO transition is a structural signal on the capital position.
Methodology & Disclaimer
For metric definitions, source-tier hierarchy, and decline-to-publish rules, see the tracker methodology. Confidence dots (• green / • amber / • red) follow the same convention as the AI Tracker.
Spotted a figure you believe is wrong? Send corrections to info@informationmatters.net.
Information Matters Framework scores are the considered opinion of the IM team — human and AI — applied to publicly-available evidence under a disclosed methodology. They are not statements of fact about the companies scored and they are not investment advice.
